Eli Lilly (LLY) is scheduled to release its Q1 earnings on May 1, and analysts continue to stay positive, holding onto Buy ratings for the ...

Swiss pharma giant Roche Holding AG RHHBY posted strong growth in the first quarter of 2025. Sales increased 7% year over ...

Wall Street’s Evan David Seigerman stirred the pot by slashing his price target on Eli Lilly stock—but not his enthusiasm.

Supported by world-class markets data from Dow Jones and FactSet, and partnering with Automated Insights, MarketWatch ...

The market expects Eli Lilly (LLY) to deliver a year-over-year increase in earnings on higher revenues when it reports results for the quarter ended March 2025. This widely-known consensus outlook is ...